Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Xie, Li Zhang, Chao-sheng He, Fei Xu, Jun-ling Liu, Zhihuang Hu, Liping Zhao, Ying Tian (2012)
Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cellsJournal of Cellular Biochemistry, 113
Yun-gang Zhang, M. Jin, Li Li, Hongying Zhao, X. Zeng, Lei Jiang, P. Wei, X. Diao, Xue Li, Qing Cao, X. Tian (2013)
Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded TissuesPLoS ONE, 8
M Reck, D Rodriguez-Abreu, AG Robinson, R Hui, T Csoszi, A Fulop, M Gottfried, N Peled, A Tafreshi, S Cuffe, M O’Brien, S Rao, K Hotta, MA Leiby, GM Lubiniecki, Y Shentu, R Rangwala, JR Brahmer (2016)
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med, 375
(2015)
Immunecheckpoint proteins VISTA and PD-1 nonredundantly regulatemurineT-cell responses
(2011)
LadanyiM,Miller VA, PaoW.Newstrategies inovercomingacquiredresistance to epidermalgrowthfactorreceptortyrosinekinaseinhibitors inlungcancer
198 Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive
(2011)
Arbeitsgruppe Pulmopathologie der O-I. Histology-based algorithm in the molecular diagnosis of mutations of the EpidernalGrowthFactorReceptor (EGFR) innon-small cell lungcancer.WienKlinWochenschr
H Isozaki, E Ichihara, N Takigawa, K Ohashi, N Ochi, M Yasugi, T Ninomiya, H Yamane, K Hotta, K Sakai, K Matsumoto, S Hosokawa, A Bessho, T Sendo, M Tanimoto, K Kiura (2016)
Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinasesCancer Res, 76
Ryohei Katayama, Tahsin Khan, C. Benes, E. Lifshits, H. Ebi, V. Rivera, W. Shakespeare, A. Iafrate, J. Engelman, A. Shaw (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 108
H. Popper, F. Wrba, U. Gruber-Mösenbacher, W. Hulla, R. Pirker, W. Hilbe, M. Studnicka, A. Mohn-Staudner, F. Ploner (2011)
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].Wiener klinische Wochenschrift, 123 9-10
(2011)
Crizotinib-resistantmutants of EML4-ALK identified through an accelerated mutagenesis
L. Mologni, S. Redaelli, A. Morandi, I. Plaza-Menacho, C. Gambacorti-Passerini (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinaseMolecular and Cellular Endocrinology, 377
(2011)
Activation of IL - 6 R / JAK 1 / STAT 3 signaling inducesDeNovo resistance to irreversible EGFR inhibitors in non - small cell lung cancer with T 790 M resistancemutation
N. Rekhtman, M. Pietanza, M. Hellmann, J. Naidoo, Arshi Arora, H. Won, D. Halpenny, Hangjun Wang, S. Tian, A. Litvak, P. Paik, A. Drilon, N. Socci, J. Poirier, R. Shen, M. Berger, A. Moreira, W. Travis, C. Rudin, M. Ladanyi (2016)
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsClinical Cancer Research, 22
Jingjing Wu, John Savooji, Delong Liu (2016)
Second- and third-generation ALK inhibitors for non-small cell lung cancerJournal of Hematology & Oncology, 9
W. Travis, E. Brambilla, A. Nicholson, Y. Yatabe, J. Austin, M. Beasley, L. Chirieac, S. Dacic, E. Duhig, D. Flieder, K. Geisinger, F. Hirsch, Y. Ishikawa, K. Kerr, M. Noguchi, G. Pelosi, C. Powell, M. Tsao, I. Wistuba (2015)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 9
Seung Lee, Boram Lee, M. Hong, Ji-Young Song, Kyungsoo Jung, Maruja Lira, Mao Mao, Joungho Han, Jhingook Kim, Yoon-La Choi (2015)
Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinomaModern Pathology, 28
AcommonBIMdeletion polymorphismmediates intrinsic resistance and inferior responses to tyrosinekinase inhibitors in cancer
NI Lindeman, PT Cagle, MB Beasley, DA Chitale, S Dacic, G Giaccone, RB Jenkins, DJ Kwiatkowski, JS Saldivar, J Squire, E Thunnissen, M Ladanyi (2013)
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyJ Thorac Oncol, 8
D Cai, H Li, R Wang, Y Li, Y Pan, H Hu, Y Zhang, R Gong, B Pan, Y Sun, H Chen (2014)
Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinomaOnco Targets Ther, 7
(2015)
ActivationofRASfamilymembers confers resistance to ROS 1 targeting drugs
(2013)
Lungadenocarcinomaexpressionprofile : one morelayerofheterogeneity
R Pirker, JR Pereira, J Pawel, M Krzakowski, R Ramlau, K Park, F Marinis, WE Eberhardt, L Paz-Ares, S Storkel, KM Schumacher, A Heydebreck, I Celik, KJ O’Byrne (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyLancet Oncol, 13
G. Frampton, Siraj Ali, M. Rosenzweig, J. Chmielecki, Xinyuan Lu, T. Bauer, M. Akimov, J. Bufill, Carrie Lee, D. Jentz, R. Hoover, S. Ou, R. Salgia, Tim Brennan, Z. Chalmers, S. Jaeger, A. Huang, J. Elvin, R. Erlich, Alex Fichtenholtz, Kyle Gowen, J. Greenbowe, Adrienne Johnson, D. Khaira, Caitlin McMahon, Eric Sanford, S. Roels, Jared White, J. Greshock, R. Schlegel, D. Lipson, R. Yelensky, D. Morosini, J. Ross, E. Collisson, M. Peters, P. Stephens, V. Miller (2015)
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Cancer discovery, 5 8
(2012)
Therapeutic strategies toovercomecrizotinib resistance in non - small cell lungcancersharboring thefusiononcogene EML 4 - ALK
H. Popper, U. Gruber-Moesenbacher, L. Müllauer, G. Hutarew, M. Vesely, R. Pirker, W. Hilbe, F. Ploner, U. Setinek, W. Hulla, H. Maier, W. Sterlacci, K. Kirchbacher, R. Kolb, M. Hochmair, G. Webersinke, E. Stacher, Patricia Grabher, T. Hernler (2013)
Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancermemo - Magazine of European Medical Oncology, 6
(2015)
RC,VialardJ,GiordanoS.ActivationofRASfamilymembers confers resistance to ROS1 targeting drugs
A. Gazdar (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 28
D. Cai, Hang Li, Rui Wang, Yuan Li, Yunjian Pan, Haichuan Hu, Yang Zhang, Ranxia Gong, Bin Pan, Yihua Sun, Haiquan Chen
Oncotargets and Therapy Dovepress Comparison of Clinical Features, Molecular Alterations, and Prognosis in Morphological Subgroups of Lung Invasive Mucinous Adenocarcinoma
(2016)
Morphological andgenetic heterogeneity inmultifocal lungadenocarcinoma : thecase ofanever - smokerwoman
(2013)
BIBF 1120 / intedanib : a new triple angiokinase inhibitor - directed therapy in patients with non - small cell lung cancer
M. Pérol, T. Ciuleanu, O. Arrieta, K. Prabhash, K. Syrigos, T. Goksel, Keunchil Park, R. Kowalyszyn, J. Pikiel, C. Lewanski, Michael Thomas, S. Dakhil, Joo‐Hang Kim, N. Karaseva, S. Yurasov, A. Zimmermann, Pablo Lee, G. Carter, M. Reck, F. Cappuzzo, E. Garon (2016)
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.Lung cancer, 93
(2013)
Foretinib is apotent inhibitorofoncogenicROS1 fusion proteins
T. Stinchcombe (2014)
Faculty Opinions recommendation of Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
T. Kosaka, E. Yamaki, A. Mogi, H. Kuwano (2011)
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung CancerJournal of Biomedicine and Biotechnology, 2011
(2012)
Exonscanningby reverse transcriptase - polymerase chain reaction for detection of known and novel EML 4 - ALK fusion variants in non - small cell lungcancer
(2012)
ChinTM,LimWT,RuanY,OngST.AcommonBIMdeletion polymorphismmediates intrinsic resistance and inferior responses to tyrosinekinase inhibitors in cancer
(2008)
The histopathology ofBRAF - V 600 E - mutated lungadenocarcinoma
(2013)
IafrateAJ,Engelman JA, ShawAT.Acquiredresistance to crizotinib from amutation in CD74-ROS1
E. Kim, Eun Cho, H. Park, A. Kim, Ji Hong, Seri Lim, J. Youn, S. Hwang, Y. Chang (2016)
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinomaBMC Cancer, 16
(2016)
ReaF, Indraccolo S.Morphological andgenetic heterogeneity inmultifocal lungadenocarcinoma: thecase ofanever-smokerwoman
C. Weeden, Benjamin Solomon, M. Asselin-Labat (2015)
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversiesCell Death Discovery, 1
E. Vassella, S. Langsch, M. Dettmer, C. Schlup, M. Neuenschwander, M. Frattini, M. Gugger, S. Schäfer (2015)
Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?Oncotarget, 6
Chenguang Li, Rong Fang, Yihua Sun, Xiangkun Han, Fei Li, Bin Gao, A. Iafrate, Xin-Yuan Liu, W. Pao, Haiquan Chen, H. Ji (2011)
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never SmokersPLoS ONE, 6
C. Rolfo, L. Raez, G. Bronte, E. Santos, K. Papadimitriou, L. Buffoni, J. Meerbeeck, A. Russo (2013)
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancerExpert Opinion on Investigational Drugs, 22
(2013)
Coexistence of PIK 3 CA and other oncogene mutations in lung adenocarcinoma - rationale for comprehensive mutationprofiling
S. Yano, S. Takeuchi, T. Nakagawa, Tadaaki Yamada (2012)
Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligandsCancer Science, 103
(2015)
Vemurafenib in multiple nonmelanomacancerswithBRAFV600mutations
K. Rajani, L. Ashbacher, T. Kinney (1978)
Pulmonary hemorrhage and systemic lupus erythematosus.The Journal of pediatrics, 93 5
(2011)
Clinicalcharacteristicsofpatientswith lung adenocarcinomas harboringBRAFmutations
P. Cagle, T. Allen, R. Olsen (2013)
Lung cancer biomarkers: present status and future developments.Archives of pathology & laboratory medicine, 137 9
InvestigatorsK - : Pembrolizumab for the treatment of non - small - cell lung cancer
(2015)
SC.Molecular profiling of lung adenosquamous carcinoma: hybrid or genuinetype?Oncotarget
(2011)
BernsA.Celloforiginof small cell lungcancer: inactivation of Trp53 andRb1 indistinct cell types of adultmouse lung
Ryohei Katayama, A. Shaw, A. Shaw, Tahsin Khan, Tahsin Khan, M. Mino‐Kenudson, B. Solomon, B. Halmos, Nicholas Jessop, J. Wain, Alan Yeo, C. Benes, L. Drew, J. Saeh, K. Crosby, L. Sequist, A. Iafrate, J. Engelman (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 4
(2012)
Newstrategies inovercomingacquiredresistance to epidermalgrowthfactorreceptortyrosinekinaseinhibitors inlungcancer
K. Kerr, L. Bubendorf, M. Edelman, A. Marchetti, T. Mok, S. Novello, K. O'Byrne, R. Stahel, S. Peters, E. Felip, B. Besse, J. Vansteenkiste, W. Eberhardt, P. Baas, M. Reck, K. Syrigos, L. Paz-Ares, E. Smit, P. Meldgaard, A. Adjei, M. Nicolson, L. Crinò, P. Schil, S. Senan, C. Faivre-Finn, G. Rocco, G. Veronesi, J. Douillard, E. Lim, C. Dooms, W. Weder, D. Ruysscher, C. Péchoux, P. Leyn, V. Westeel (2014)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 25 9
M. Xie, Chao-sheng He, Shenhai Wei, Li Zhang (2013)
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.European journal of cancer, 49 16
J. Chaft, M. Arcila, P. Paik, C. Lau, Gregory Riely, M. Pietanza, M. Zakowski, V. Rusch, C. Sima, M. Ladanyi, M. Kris (2011)
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation ProfilingMolecular Cancer Therapeutics, 11
Huiyong Sun, Youyong Li, Sheng Tian, Junmei Wang, Tingjun Hou (2014)
P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy LandscapePLoS Computational Biology, 10
Ryohei Katayama, Yuka Kobayashi, L. Friboulet, Elizabeth Lockerman, S. Koike, A. Shaw, J. Engelman, N. Fujita (2014)
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive CancerClinical Cancer Research, 21
H. Yu, M. Arcila, N. Rekhtman, C. Sima, M. Zakowski, W. Pao, M. Kris, V. Miller, M. Ladanyi, Gregory Riely (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 19
K. Takeuchi, M. Soda, Yuki Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, Y. Ishikawa (2012)
RET, ROS1 and ALK fusions in lung cancerNature Medicine, 18
A. Geles, U. Gruber-Moesenbacher, F. Quehenberger, C. Manzl, Mohamed Effah, E. Grygar, F. Juettner-Smolle, H. Popper (2015)
Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survivalVirchows Archiv, 467
H. Sanders, Hai-rong Li, J. Bruey, J. Scheerle, A. Meloni-Ehrig, J. Kelly, Constance Novick, M. Albitar (2011)
Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.Cancer genetics, 204 1
P. Paik, A. Varghese, C. Sima, A. Moreira, M. Ladanyi, M. Kris, N. Rekhtman (2012)
Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like ComponentMolecular Cancer Therapeutics, 11
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
N. Lindeman, P. Cagle, M. Beasley, D. Chitale, S. Dacic, G. Giaccone, R. Jenkins, D. Kwiatkowski, J. Saldivar, J. Squire, E. Thunnissen, M. Ladanyi (2013)
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Archives of pathology & laboratory medicine, 137 6
P Cagle (2016)
Revision of the CAP/IASLC/AMP molecular testing guidelines for lung caner biomarkers
W. Cai, D. Lin, Chunyan Wu, Xue-Fei Li, Chao Zhao, Li-mou Zheng, S. Chuai, K. Fei, Caicun Zhou, F. Hirsch (2015)
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 32
Y. Suehara, M. Arcila, Lu Wang, Adnan Hasanovic, D. Ang, Tatsuo Ito, Y. Kimura, A. Drilon, U. Guha, V. Rusch, M. Kris, M. Zakowski, N. Rizvi, R. Khanin, M. Ladanyi (2012)
Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase FusionsClinical Cancer Research, 18
Keunchil Park, Joo‐Hang Kim, E. Cho, Jin-Hyoung Kang, J. Shih, A. Zimmermann, Pablo Lee, Ekaterine Alexandris, T. Puri, M. Orlando (2016)
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)Cancer Research and Treatment : Official Journal of Korean Cancer Association, 48
J. Ryu (2018)
Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Sun Kim, O. Kwon, Y. Hong, J. Kim, F. Solca, S. Ha, R. Soo, J. Christensen, J. Lee, B. Cho (2012)
Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance MutationMolecular Cancer Therapeutics, 11
A. Shaw, B. Yeap, B. Solomon, Gregory Riely, J. Gainor, J. Engelman, G. Shapiro, D. Costa, S. Ou, M. Butaney, R. Salgia, R. Maki, M. Varella-Garcia, R. Doebele, Y. Bang, K. Kulig, P. Selaru, Yiyun Tang, K. Wilner, E. Kwak, Jeffrey Clark, A. Iafrate, D. Camidge (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.The Lancet. Oncology, 12 11
(2015)
Comprehensive analysis of RET and ROS1rearrangementinlungadenocarcinoma.ModPathol
Li Wang, I. Mercier, J. Putra, Wenna Chen, J. Liu, A. Schenk, E. Nowak, A. Suriawinata, Jiannan Li, R. Noelle (2014)
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunityProceedings of the National Academy of Sciences, 111
C. Lovly, W. Pao (2012)
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome ResistanceScience Translational Medicine, 4
G. Pelosi, A. Pellegrinelli, A. Fabbri, E. Tamborini, F. Perrone, G. Settanni, A. Busico, Benedetta Picciani, M. Testi, L. Militti, P. Maisonneuve, B. Valeri, A. Sonzogni, C. Proto, M. Garassino, F. Braud, U. Pastorino (2016)
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodulesVirchows Archiv, 468
Yanxia Guo, Adele Wang (2015)
Novel Immune Check-Point Regulators in Tolerance MaintenanceFrontiers in Immunology, 6
P Hofman, HH Popper (2016)
Pathologists and liquid biopsies: to be or not to be?Virchows Arch
J. Chaft, A. Litvak, M. Arcila, Payal Patel, S. D’Angelo, L. Krug, V. Rusch, Alicia Mattson, C. Coeshott, Bernard Park, D. Apelian, M. Kris, C. Azzoli (2014)
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.Clinical lung cancer, 15 6
Sen Zhang, Frank Wang, J. Keats, Xiaotian Zhu, Y. Ning, Scott Wardwell, Lauren Moran, Qurish Mohemmad, R. Anjum, Yihan Wang, N. Narasimhan, D. Dalgarno, W. Shakespeare, J. Miret, T. Clackson, V. Rivera (2011)
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis ScreenChemical Biology & Drug Design, 78
special report Non - small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosinekinases
(2016)
Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive
D. Costa, K. Nguyen, B. Cho, L. Sequist, D. Jackman, Gregory Riely, B. Yeap, B. Halmos, J. Kim, P. Jänne, M. Huberman, W. Pao, D. Tenen, Susumu Kobayashi (2008)
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to GefitinibClinical Cancer Research, 14
(2015)
LeTM,HaggstromDE,Gentzler RD.Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer(NSCLC).TranslLungCancerRes
(2011)
LadanyiM,RielyGJ.Clinicalcharacteristicsofpatientswith lung adenocarcinomas harboringBRAFmutations
(2011)
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRASmutations
(2016)
Celloforiginof small cell lungcancer : inactivation of Trp 53 andRb 1 indistinct cell types of adultmouse lung
R. Hall, Tri Le, D. Haggstrom, R. Gentzler (2015)
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Translational lung cancer research, 4 5
(2016)
Impairedc - met receptordegradationmediated byMET Exon 14 mutations in non - small - cell lung cancer
(2016)
The blueprint project: comparing PD-L1 IHC diagnostics for immune checkpoint inhibition
(2013)
Acquired Resistance to Crizotinib from a Mutation in CD 74 – ROS 1
The introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the therapy of non-small cell lung cancer (NSCLC) with activating mutations of the EGF receptor has opened a new area of lung cancer treatment strategies and led to an enthusiastic search for additional genetic aberrations. Genetic drivers such as EML4-ALK (EML4: echinoderm microtubule-associated protein-like 4; ALK: anaplastic lymphoma kinase) and proto-oncogene tyrosine protein kinase transcribed from the ROS1-gene (ROS1) rearrangements have been detected and specific treatment options have been developed. A new approach to treatment in lung cancer is immunotherapy by antibodies interfering with immune checkpoint controls. Diagnostic and predictive immunohistochemical staining and molecular tests have to follow specific rules, if applied in daily practice. The Austrian Working Group on Pulmonary Pathology and Oncology (AWGPPO) has presented an updated version of the previous recommendations published in 2013. Questions raised during the past 3 years will be addressed: selection of tissue, order of diagnostic immunohistochemical and molecular tests, “reflex” testing, the issue of resistance mechanisms, significance of liquid biopsies, and use and interpretation of antibody reactions for immune checkpoint markers.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Nov 30, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.